Protagonist Announces New Icotrokinra Data
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis.
- 31.7% of patients achieved clinical remission
- 38.1% showed endoscopic improvement versus placebo
Based on results from the Phase 2b ANTHEM-UC study, Johnson & Johnson has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC.
New long-term 52-week data from the Phase 3 ICONIC-TOTAL study show icotrokinra demonstrated high and durable rates of site-specific psoriasis clearance.
Author's summary: Icotrokinra shows promise in ulcerative colitis and plaque psoriasis treatments.
More News
- Tennis takes first loss in Sweet 16 - Davie County Enterprise Record
- A Wake-Up Call for Iran’s Banking System
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Travelzoo: Q3 Earnings Snapshot - WTOP News
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- Donald Trump endorses Republican Jeff Hurd's bid for reelection bid in Colorado's 3rd CD
- Families fish, bond at Trees Lake event - News
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Ehlmann Announces Reelection Bid for St. Charles County Executive in 2026 - The Missouri Times